Brief: Matinas BioPharma Announces Topline Results From ENHANCE-IT Study of LYPDISO Against Vascepa

Matinas BioPharma Holdings

01/02/2021 11:11

Feb 1 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA ANNOUNCES TOPLINE RESULTS FROM
ENHANCE-IT
STUDY OF LYPDISO™ AGAINST VASCEPA®
    * MATINAS BIOPHARMA HOLDINGS - LYPDISO DEMONSTRATED 
STATISTICALLY
SIGNIFICANT 46% RELATIVE PERCENT INCREASE IN EPA CHANGE FROM
BASELINE OVER VASCEPA
    * MATINAS BIOPHARMA HOLDINGS INC - LYPDISO DEMONSTRATED A
39%
RELATIVE DIFFERENCE IN RESPONSE OVER VASCEPA IN TG REDUCTION IN
ENHANCE-IT STUDY
    * MATINAS BIOPHARMA HOLDINGS INC - PRIMARY ENDPOINT DID NOT
MEET
STATISTICAL SIGNIFICANCE OVER VASCEPA
    * MATINAS BIOPHARMA HOLDINGS INC - PER PROTOCOL ANALYSIS
DEMONSTRATED STATISTICAL SIGNIFICANCE AND SUPERIORITY VERSUS.
VASCEPA
    * MATINAS BIOPHARMA - NO SERIOUS ADVERSE EVENTS REPORTED FOR
ENHANCE-IT STUDY AND NO DROPOUTS RELATED TO STUDY DRUG ADVERSE
EVENTS

Source text for Eikon:  ID:nGNXFNzHL 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))